Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies

Computational and Structural Biotechnology Journal

Volumn 14, Issue , 2016, Pages 357-362

  Ruella, Marco ^a,b   Maus, Marcela V ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adoptive cell therapy; biCAR; Bispecific antibodies; Blinatumomab; CART19; Chimeric antigen receptor T cells; CTL019; dualCART; Leukemia; tanCAR

Indexed keywords

ANTIGENS; CELL ENGINEERING; CELL MEMBRANES; CYTOLOGY; DIAGNOSIS; DISEASES; T-CELLS;

ADOPTIVE CELL THERAPY; ANTIGEN RECEPTORS; BICAR; BISPECIFIC ANTIBODY; BLINATUMOMAB; CART19; CELL THERAPY; CHIMERIC ANTIGEN RECEPTOR T CELL; CTL019; DUALCART; LEUKEMIA; TANCAR;

ANTIBODIES;

BLINATUMOMAB; CD19 ANTIGEN; TISAGENLECLEUCEL T;

CANCER IMMUNOTHERAPY; DRUG TARGETING; HUMAN; LEUKEMIA; LEUKEMIA CELL; LEUKEMIA RELAPSE; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN DEPLETION; SHORT SURVEY; TUMOR ESCAPE;

EID: 84991501323     PISSN: None     EISSN: 20010370     Source Type: Journal    
DOI: 10.1016/j.csbj.2016.09.003     Document Type: Short Survey

References (58)

1. [1] Ruella, M., Kalos, M., Adoptive immunotherapy for cancer. Immunol Rev 257:1 (2014), 14–38, 10.1111/imr.12136.
2. [2] Ruella, M., June, C.H., Chimeric antigen receptor T cells for B cell neoplasms: choose the right CAR for you. Curr Hematol Malig Rep, 2016, 10.1007/s11899-016-0336-z.
3. [3] Ruella, M., Gill, S., How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia. Expert Opin Biol Ther 15:6 (2015), 761–766, 10.1517/14712598.2015.1009888.
4. [4] Przepiorka, D., Ko, C.W., Deisseroth, A., Yancey, C.L., Candau-Chacon, R., Chiu, H.J., et al. FDA approval: blinatumomab. Clin Cancer Res 21:18 (2015), 4035–4039, 10.1158/1078-0432.CCR-15-0612.
5. [5] Haas, C., Krinner, E., Brischwein, K., Hoffmann, P., Lutterbuse, R., Schlereth, B., et al. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 214:6 (2009), 441–453, 10.1016/j.imbio.2008.11.014.
6. [6] Loffler, A., Kufer, P., Lutterbuse, R., Zettl, F., Daniel, P.T., Schwenkenbecher, J.M., et al. A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95:6 (2000), 2098–2103.
7. [7] Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321:5891 (2008), 974–977, 10.1126/science.1158545.
8. [8] Gruen, M., Bommert, K., Bargou, R.C., T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent. Cancer Immunol Immunother 53:7 (2004), 625–632, 10.1007/s00262-003-0496-2.
9. [9] Klinger, M., Brandl, C., Zugmaier, G., Hijazi, Y., Bargou, R.C., Topp, M.S., et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 119:26 (2012), 6226–6233, 10.1182/blood-2012-01-400515.
10. [10] Topp, M.S., Gokbuget, N., Stein, A.S., Zugmaier, G., O'Brien, S., Bargou, R.C., et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 16:1 (2015), 57–66, 10.1016/S1470-2045(14)71170-2.
11. [11] Gross, G., Waks, T., Eshhar, Z., Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A 86:24 (1989), 10024–10028.
12. [12] Kuwana, Y., Asakura, Y., Utsunomiya, N., Nakanishi, M., Arata, Y., Itoh, S., et al. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun 149:3 (1987), 960–968.
13. [13] Milone, M.C., Fish, J.D., Carpenito, C., Carroll, R.G., Binder, G.K., Teachey, D., et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 17:8 (2009), 1453–1464, 10.1038/mt.2009.83.
14. [14] Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371:16 (2014), 1507–1517, 10.1056/NEJMoa1407222.
15. [15] Lee, D.W., Kochenderfer, J.N., Stetler-Stevenson, M., Cui, Y.K., Delbrook, C., Feldman, S.A., et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385:9967 (2015), 517–528, 10.1016/S0140-6736(14)61403-3.
16. [16] Park, J.H., Riviere, I., Wang, X., Bernal, Y., Purdon, T., Halton, E., et al. Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL. J Clin Oncol, 33(15), 2015.
17. [17] Turtle, C.J., Hanafi, L.A., Berger, C., Gooley, T.A., Cherian, S., Hudecek, M., et al. CD19 CAR-T cells of defined CD4 +:CD8 + composition in adult B cell ALL patients. J Clin Invest, 2016, 10.1172/JCI85309.
18. [18] Topp, M.S., Gokbuget, N., Zugmaier, G., Degenhard, E., Goebeler, M.E., Klinger, M., et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120:26 (2012), 5185–5187, 10.1182/blood-2012-07-441030.
19. [19] Topp, M.S., Kufer, P., Gokbuget, N., Goebeler, M., Klinger, M., Neumann, S., et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 29:18 (2011), 2493–2498, 10.1200/JCO.2010.32.7270.
20. [20] Goekbuget, N.D.H., Bonifacio, M., Reichle, A., Graux, C., Havelange, V., Buss, E.C., Faul, C., Bruggemann, M., Ganser, A., Stieglmaier, J., Wessels, H., Haddad, V., Zugmaier, G., Nagorsen, D., Bargou, R.C., BLAST: a confirmatory, single-arm, phase 2 study of blinatumomab, a bispecific T-cell engager (BiTE®) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL). American Society of Hematology Annual (ASH) Meeting 2014, 2014 (Abs #379).
21. [21] Gökbuget, N.H.D., Bonifacio, M., Reichle, A., Graux, C., Faul, C., Diedrich, H., Topp, M.S., Brüggemann, M., Horst, H.A., Stieglmaier, J., Wessels, H., Haddad, V., Zugmaier, G., Nagorsen, D., Bargou, R.C., Long-term outcomes after blinatumomab treatment: follow-up of a phase 2 study in patients (Pts) with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukemia (ALL). Blood Cancer J, 126(23), 2015.
22. [22] Topp, M.S., Gokbuget, N., Zugmaier, G., Klappers, P., Stelljes, M., Neumann, S., et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol, 2014, 10.1200/JCO.2014.56.3247.
23. [23] Arend von Stackelberg, A.L.F., Zugmaier, G., Handgretinger, R., Trippett, T.M., Rizzari, C., Zwaan, C.M., Bhojwani, D., Dubois, S.G., Bader, P., Borkhardt, A., O'Brien, M., Rheingold, S.R., Cooper, T.M., Hu, K., Mergen, N., Fischer, A., Zhu, M., Hijazi, Y., Whitlock, J., Gore, L., Phase 1/2 study in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) receiving blinatumomab treatment. American Society of Hematology Annual (ASH) Meeting 2014, 2014 (Abs #2292).
24. [24] Martinelli, G.D.H., Chevallier, P., Ottmann, O., Gokbuget, N., Topp, M., (Complete molecular and hematologic response in adult patients with relapsed/refractory (R/R) Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia (ALL) following treatment with blinatumomab: results from a phase 2 single-arm, multicenter study (Alcantara). Blood, 126(23), 2015, 679.
25. [25] Davila, M.L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med, 6(224), 2014, 224ra25, 10.1126/scitranslmed.3008226.
26. [26] Shannon, L., Maude, D.T.T., Rheingold, S.R., Shaw, P.A., Aplenc, R., Barrett, D.M., Barker, C.S., Callahan, C., Frey, N.V., Nazimuddin, F., Lacey, S.F., Zheng, Z., Levine, B., Melenhorst, J.J., Motley, L., Porter, D.L., June, C.H., Grupp, S.A., Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL. J Clin Oncol, 31, 2016, 34 (suppl; abstr 3011).
27. [27] Hochhaus, A., Ernst, T., Eigendorff, E., La Rosee, P., Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients. Ann Hematol 94:Suppl. 2 (2015), S133–S140, 10.1007/s00277-015-2323-1.
28. [28] Manzano, J.L., Layos, L., Buges, C., de Los Llanos Gil, M., Vila, L., Martinez-Balibrea, E., et al. Resistant mechanisms to BRAF inhibitors in melanoma. Ann Transl Med, 4(12), 2016, 237, 10.21037/atm.2016.06.07.
29. [29] Zugmaier, G., Gokbuget, N., Klinger, M., Viardot, A., Stelljes, M., Neumann, S., et al. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood 126:24 (2015), 2578–2584, 10.1182/blood-2015-06-649111.
30. [30] Yannakou, C.K., Came, N., Bajel, A.R., Juneja, S., CD19 negative relapse in B-ALL treated with blinatumomab therapy: avoiding the trap. Blood, 126(23), 2015, 4983-.
31. [31] Grupp, S.A., Maude, S.L., Shaw, P.A., Aplenc, R., Barrett, D.M., Callahan, C., et al. Durable remissions in children with relapsed/refractory all treated with t cells engineered with a CD19-targeted chimeric antigen receptor (CTL019). Blood, 126(23), 2015, 681.
32. [32] Lee, D.W., Kochenderfer, J.N., Stetler-Stevenson, M., Cui, Y.K., Delbrook, C., Feldman, S.A., et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet, 2014, 10.1016/S0140-6736(14)61403-3.
33. [33] Khalil, D.N., Smith, E.L., Brentjens, R.J., Wolchok, J.D., The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol, 13(6), 2016, 394, 10.1038/nrclinonc.2016.65.
34. [34] Sotillo, E., Barrett, D.M., Black, K.L., Bagashev, A., Oldridge, D., Wu, G., et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 5:12 (2015), 1282–1295, 10.1158/2159-8290.CD-15-1020.
35. [35] Jacoby, E., Nguyen, S.M., Fountaine, T.J., Welp, K., Gryder, B., Qin, H., et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat Commun, 7, 2016, 12320, 10.1038/ncomms12320.
36. [36] Gardner, R., Wu, D., Cherian, S., Fang, M., Hanafi, L.A., Finney, O., et al. Acquisition of a CD19 negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T cell therapy. Blood, 2016, 10.1182/blood-2015-08-665547.
37. [37] Rayes, A., McMasters, R.L., O'Brien, M.M., Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy. Pediatr Blood Cancer 63:6 (2016), 1113–1115, 10.1002/pbc.25953.
38. [38] Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D., Rheingold, S., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368:16 (2013), 1509–1518, 10.1056/NEJMoa1215134.
39. [39] Ruella, M., Barrett, D.M., Kenderian, S.S., Shestova, O., Hofmann, T.J., Perazzelli, J., et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest, 2016, 10.1172/JCI87366.
40. [40] Evans, A.G., Rothberg, P.G., Burack, W.R., Huntington, S.F., Porter, D.L., Friedberg, J.W., et al. Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells. Br J Haematol, 2015, 10.1111/bjh.13562.
41. [41] Haso, W., Lee, D.W., Shah, N.N., Stetler-Stevenson, M., Yuan, C.M., Pastan, I.H., et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121:7 (2013), 1165–1174, 10.1182/blood-2012-06-438002 (blood-2012-06-438002 [pii]).
42. [42] Qin, H., Zhang, L., Orentas, R.J., Fry, T.J., CD22-targeted chimeric antigen receptor (CAR) T cells containing the 4-1BB costimulatory domain demonstrate enhanced persistence and superior efficacy against B-cell precursor acute lymphoblastic leukemia (ALL) compared to those containing CD28. Blood, 122(21), 2013, 1431-.
43. [43] Fry, T.J., Stetler-Stevenson, M., Shah, N.N., Yuan, C.M., Yates, B., Delbrook, C., et al. Clinical activity and persistence of anti-CD22 chimeric antigen receptor in children and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL). Blood, 126(23), 2015, 1324-.
44. [44] Kantarjian, H.M., DeAngelo, D.J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med, 2016, 10.1056/NEJMoa1509277.
45. [45] Hegde, M., Corder, A., Chow, K.K., Mukherjee, M., Ashoori, A., Kew, Y., et al. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther 21:11 (2013), 2087–2101, 10.1038/mt.2013.185.
46. [46] Grada, Z., Hegde, M., Byrd, T., Shaffer, D.R., Ghazi, A., Brawley, V.S., et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids, 2, 2013, e105, 10.1038/mtna.2013.32.
47. [47] Hegde, M., Mukherjee, M., Grada, Z., Pignata, A., Landi, D., Navai, S.A., et al. Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape. J Clin Invest 126:8 (2016), 3036–3052, 10.1172/JCI83416.
48. [48] Anurathapan, U., Chan, R.C., Hindi, H.F., Mucharla, R., Bajgain, P., Hayes, B.C., et al. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther 22:3 (2014), 623–633, 10.1038/mt.2013.262.
49. [49] O'Rourke, D.M., Nasrallah, M., Morrissette, J.J., Melenhorst, J.J., Lacey, S.F., Mansfield, K., et al. Pilot study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII + glioblastoma. ASCO meeting abstracts, 34(15_suppl), 2016, 2067.
50. [50] Qin, H., Haso, W., Nguyen, S.M., Fry, T.J., Preclinical development of bispecific chimeric antigen receptor targeting both CD19 and CD22. Blood, 126(23), 2015, 4427-.
51. [51] Zah, E., Lin, M.Y., Silva-Benedict, A., Jensen, M.C., Chen, Y.Y., T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res, 2016, 10.1158/2326-6066.CIR-15-0231.
52. [52] Somasundaram, C., Sundarapandiyan, K., Keler, T., Deo, Y.M., Graziano, R.F., Development of a trispecific antibody conjugate that directs two distinct tumor-associated antigens to CD64 on myeloid effector cells. Hum Antibodies 9:1 (1999), 47–54.
53. [53] Spiess, C., Zhai, Q., Carter, P.J., Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol 67:2 Pt A (2015), 95–106, 10.1016/j.molimm.2015.01.003.
54. [54] Kugler, M., Stein, C., Kellner, C., Mentz, K., Saul, D., Schwenkert, M., et al. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Br J Haematol 150:5 (2010), 574–586, 10.1111/j.1365-2141.2010.08300.x.
55. [55] Schubert, I., Kellner, C., Stein, C., Kugler, M., Schwenkert, M., Saul, D., et al. A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting. mAbs 3:1 (2011), 21–30.
56. [56] Herrera, L., Yarbrough, S., Ghetie, V., Aquino, D.B., Vitetta, E.S., Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins. Leukemia 17:2 (2003), 334–338, 10.1038/sj.leu.2402790.
57. [57] Bachanova, V., Frankel, A.E., Cao, Q., Lewis, D., Grzywacz, B., Verneris, M.R., et al. Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies. Clin Cancer Res 21:6 (2015), 1267–1272, 10.1158/1078-0432.CCR-14-2877.
58. [58] DeVita, V.T. Jr., Chu, E., A history of cancer chemotherapy. Cancer Res 68:21 (2008), 8643–8653, 10.1158/0008-5472.CAN-07-6611.